罗莫佐单抗与甲状旁腺激素类似物治疗骨质疏松的心血管安全性比较:倾向评分匹配队列研究
基于TriNetX全球 federated 健康研究网络(113家机构、16国、136460930例患者)的真实世界数据,纳入≥40岁骨质疏松并接受罗莫佐单抗或甲状旁腺激素类似物(特立帕肽/阿巴洛肽)处方的患者,经1:1倾向评分匹配后每组5610例。随访1年内,罗莫佐单抗组3P-MACE显著少于PTH类似物组(158例 vs 211例,P=.003)。
要点
- 罗莫佐单抗组1年3P-MACE发生率显著低于PTH类似物组(158例 vs 211例,P=.003)。
- 心肌缺血事件罗莫佐单抗组31例 vs PTH类似物组58例(P=.003)。
- 脑血管事件罗莫佐单抗组56例 vs PTH类似物组79例(P=.037);死亡83例 vs 104例(P=.099)。
核心结论
- 在多样化的真实世界环境中,罗莫佐单抗用于骨质疏松与PTH类似物治疗相比,与更少的心血管不良事件相关。
研究设计与样本
- 倾向评分匹配队列研究,数据来自TriNetX全球 federated 健康研究网络,分析时涵盖16个国家113家医疗机构的136460930例患者实时电子病历。
- 纳入标准为年龄≥40岁、诊断为骨质疏松,且在2019年8月至2022年8月期间处方罗莫佐单抗或PTH类似物(特立帕肽/阿巴洛肽)。
- 罗莫佐单抗组5626例、PTH类似物组15986例符合标准,经1:1倾向评分匹配(依据人口学变量、合并症和用药)后每组5610例。
- 采用Kaplan-Meier分析估计结局概率,结局指标为初始处方后1年随访期间新发3点主要不良心血管事件或死亡(3P-MACE)。
主要发现
- 3P-MACE在罗莫佐单抗组显著少于PTH类似物组(158例 vs 211例,P=.003)。
- 心肌缺血事件罗莫佐单抗组31例 vs PTH类似物组58例(P=.003)。
- 脑血管事件罗莫佐单抗组56例 vs PTH类似物组79例(P=.037)。
- 死亡罗莫佐单抗组83例 vs PTH类似物组104例(P=.099)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Romosozumab, a monoclonal sclerostin antibody, is a recently approved highly potent antiosteoporotic agent with osteoanabolic properties. Clinical use of romosozumab is hindered by the fear of adverse cardiovascular (CV) events raised following the pivotal ARCH trial. OBJECTIVE: This work aimed to assess real-world CV safety of romosozumab vs alternative osteoanabolic therapies used for treatment of severe osteoporosis. METHODS: Data were obtained from TriNetX, a global federated health research network including real-time electronic medical records from 113 health care organizations with 136 460 930 patients across 16 countries at time of analysis. Inclusion criteria were age 40 years or older, a diagnosis of osteoporosis and prescription of romosozumab or a parathyroid hormone (PTH) analogue (teriparatide/abaloparatide) during August 2019 through August 2022. Propensity-score-matched cohorts were created 1:1 using demographic variables, comorbidities, and medications. Kaplan-Meier analysis was used to estimate the probability of the outcomes. Outcome measures included incident 3-point major adverse CV event or death (3P-MACE) during 1-year of follow-up after the initial prescription. RESULTS: A total of 5626 and 15 986 patients met the criteria for romosozumab and PTH analogue cohorts, respectively, with 5610 patients per group following propensity score matching. 3P-MACE was significantly less frequent in the romosozumab vs PTH analogue cohort (158 vs 211 patients with an outcome; P = .003) with reductions in the individual components of the composite outcome: myocardial ischemic events (31 vs 58; P = .003); cerebrovascular events 56 vs 79; P = .037; deaths (83 vs 104; P = .099). CONCLUSION: In a diverse, real-world setting, prescription of romosozumab for osteoporosis is associated with fewer adverse CV events when compared to PTH analogue therapy.
引用
- Stokar J, Szalat A. Cardiovascular Safety of Romosozumab vs PTH Analogues for Osteoporosis Treatment: A Propensity-Score-Matched Cohort Study. J Clin Endocrinol Metab. 2025. PMID: 38482603. doi:10.1210/clinem/dgae173
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。